天臣医疗（688013）8月27日主力资金净卖出355.81万元

Core Viewpoint - Tianchen Medical (688013) has shown a positive performance with a closing price of 50.8 yuan, reflecting a 1.6% increase as of August 27, 2025, amidst varying capital flows [1][2]. Financial Performance - The company reported a main revenue of 156 million yuan for the first half of 2025, representing a year-on-year increase of 17.66% [4]. - The net profit attributable to shareholders was 48.21 million yuan, up 67.1% year-on-year [4]. - The second quarter of 2025 saw a single-quarter main revenue of 90.32 million yuan, a 24.56% increase year-on-year, and a net profit of 35.02 million yuan, which is a 100.15% increase year-on-year [4]. Capital Flow Analysis - On August 27, 2025, the net outflow of main funds was 3.56 million yuan, accounting for 1.62% of the total transaction amount, while retail funds saw a net outflow of 495,300 yuan [1]. - Over the past five days, the financing balance increased to 128 million yuan, with a net financing purchase of 7.23 million yuan on August 27 [2]. Industry Comparison - Tianchen Medical's total market value is 4.123 billion yuan, significantly lower than the industry average of 12.081 billion yuan, ranking 89th out of 123 in the medical device industry [4]. - The company's net profit margin stands at 30.87%, which is considerably higher than the industry average of 11.01%, ranking 14th in the industry [4]. - The company's gross margin is 63.03%, surpassing the industry average of 51.64%, ranking 44th in the industry [4].